Similar articles

• Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.

  Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC. Sheng WH, et al. Clin Infect Dis. 2007 Nov 1;45(9):1221-9. doi: 10.1086/522173. Epub 2007 Sep 21. Clin Infect Dis. 2007. PMID: 17918088
• [Atypical serologic patterns in hepatitis B virus infection].

  Muñoz Criado S, Muñoz Bellido JL, García Rodríguez JA. Muñoz Criado S, et al. Rev Clin Esp. 1997 Jul;197(7):507-11. Rev Clin Esp. 1997. PMID: 9411549 Review. Spanish. No abstract available.
• Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy.

  Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V. Siriaksorn S, et al. Vaccine. 2006 Apr 12;24(16):3095-9. doi: 10.1016/j.vaccine.2006.01.045. Epub 2006 Feb 6. Vaccine. 2006. PMID: 16488516
• Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor.

  Carr A, Cooper DA. Carr A, et al. Lancet. 1997 Apr 5;349(9057):995-6. doi: 10.1016/S0140-6736(05)62892-9. Lancet. 1997. PMID: 9100629 No abstract available.
• Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature.

  Rouphael NG, Talati NJ, Rimland D. Rouphael NG, et al. AIDS. 2007 Mar 30;21(6):771-4. doi: 10.1097/QAD.0b013e3280ad47f5. AIDS. 2007. PMID: 17413702 Review.